1995

Long-Term Effectiveness of Combined Alprazolam and Cognitive-Behavioral Therapies in Panic Disorder

Steven M. Bond '95
Illinois Wesleyan University

Recommended Citation
http://digitalcommons.iwu.edu/psych_honproj/112

This Article is brought to you for free and open access by The Ames Library, the Andrew W. Mellon Center for Curricular and Faculty Development, the Office of the Provost and the Office of the President. It has been accepted for inclusion in Digital Commons @ IWU by the faculty at Illinois Wesleyan University. For more information, please contact digitalcommons@iwu.edu.
©Copyright is owned by the author of this document.
Running Head: LONG-TERM EFFECTIVENESS OF COMBINED THERAPIES

Long-term Effectiveness of Combined Alprazolam and Cognitive-Behavioral Therapies in Panic Disorder

Steven M. Bond\textsuperscript{1} and Timothy J. Bruce\textsuperscript{2}

\textsuperscript{1}Illinois Wesleyan University
\textsuperscript{2}UICOMP
# Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Title</td>
<td>1</td>
</tr>
<tr>
<td>Table of Contents</td>
<td>2</td>
</tr>
<tr>
<td>Abstract</td>
<td>3</td>
</tr>
<tr>
<td>Acknowledgements</td>
<td>4</td>
</tr>
<tr>
<td>Introduction</td>
<td>6</td>
</tr>
<tr>
<td>Method</td>
<td>12</td>
</tr>
<tr>
<td>Results</td>
<td>17</td>
</tr>
<tr>
<td>Discussion</td>
<td>19</td>
</tr>
<tr>
<td>References</td>
<td>23</td>
</tr>
<tr>
<td>Appendix A</td>
<td>28</td>
</tr>
<tr>
<td>Appendix B</td>
<td>32</td>
</tr>
<tr>
<td>Appendix C</td>
<td>33</td>
</tr>
<tr>
<td>Appendix D</td>
<td>35</td>
</tr>
<tr>
<td>Appendix E</td>
<td>36</td>
</tr>
<tr>
<td>Appendix F</td>
<td>37</td>
</tr>
<tr>
<td>Appendix G</td>
<td>38</td>
</tr>
<tr>
<td>Figure Legend and Footnote</td>
<td>40</td>
</tr>
<tr>
<td>Figure 1</td>
<td>41</td>
</tr>
<tr>
<td>Figures 2-8</td>
<td>42</td>
</tr>
</tbody>
</table>
Abstract

Benzodiazepines, particularly alprazolam, have been shown to be effective in the acute treatment of panic disorder. Difficult withdrawal and high relapse rates after successful discontinuation continue to be problems with this class of medication. Recent studies instituting cognitive-behavioral therapy as a treatment supplement to alprazolam taper, have shown promising results out to one year follow-up. The present study investigated whether that combined treatment results in long-term improvement. Patients were stabilized on alprazolam and randomly assigned to either an alprazolam-only group or the same condition with twelve weeks of concurrent cognitive-behavioral therapy. Twenty patients completed the study. During the 24-48-month post-treatment evaluation, nearly 70% of those receiving combined treatment had remained off drug or other supportive panic disorder therapy compared to the 30% for the alprazolam-only group. From scores on self-report and clinician-rated measures, the combined treatment appeared to have been effective in producing a high end-state functioning as well as in facilitating alprazolam discontinuation.
Acknowledgements

The completion of this project could not have occurred without the invaluable assistance, guidance, and input from my committee members and close friends. Mentioning your names here does not do justice to the time you sacrificed to see that my research was conducted and reported properly.

I extend my appreciation to Dr. Jim Dougan, Dr. Johanna Shapiro, and Dr. Given Harper for your seasoned minds and critical eyes. You made many suggestions for improvement and outlined the weaknesses that needed to be addressed. What I have learned now will, no doubt, change the way I approach research in graduate school and in the rest of my professional career.

To my peers, I would like to thank two individuals in particular: Laura Chapman and Leann Westerhold. Though our research opportunities diverged this last year, Laura and I remained close friends, sharing experiences in both academic and social spheres. Her moral support and an attentive ear are endearing qualities that I made use of many times when no one else would understand.

And Leann, whose ability to endure so many of my not-even-remotely-funny stories en route to Peoria, helped me to see the proverbial light at the end of the Psych 401 tunnel by reminding me that everything will, indeed, get done. Though the times were busy,
the fellowship was memorable, and an enduring friendship, I hope will be born of our mutual experiences this year.

As for Dr. Bruce, Tim Bruce, whose insistence that I take up the way of the King if I am ever going to make it in Memphis, I owe far more than some trivia book or roll of tube socks. For the countless hours spent revising personal statements, proposal drafts, and final papers, I pause, face the northeast, and thank the Great Rastor that this man, who does whatever he does between the hours of 11 a.m. and 2 p.m., has bestowed upon me the years of wisdom that can only come from seeing Barry Manilow naked, having a millionaire brother, and asking rhetorically, "Is that Mother Green?"
Long-term Effectiveness of Combined Alprazolam and Cognitive-Behavioral Therapies in Panic Disorder

Panic disorder with agoraphobia (PDA), which has a prevalence of one to two percent in the general population, typically begins in a patient's mid-twenties and occurs twice as frequently in women as in men (24). Like all anxiety disorders, it has the trademark symptoms of anxiety and avoidance. However, PDA can be distinguished from other anxiety disorders, especially phobias, by the characteristic "spontaneous" panic attacks, which are not reliably and exclusively elicited by some specific object or situation. Consequently, panic patients can experience the attacks with no forewarning and no predictive stimulus (14). During the attacks patients may experience any of the following symptoms: shortness of breath, dizziness, tachycardia, trembling or shaking, sweating, choking, nausea, hot flashes or chills, feelings of numbness or tingling, depersonalization/derealization, a fear of dying, or a fear of going crazy without the ability to control one's actions. To meet the diagnostic criteria for PDA, a patient must experience at least four of these symptoms during a panic attack and begin avoiding situations for fear of their recurrence (2).

In agoraphobia, patients tend to modify their activities in order to avoid situations in which escape might be difficult or impossible, help may not be available, or embarrassment might result if another panic attack occurred. This modification, termed "fear of fear", is often targeted in the course of treatment (15). Certainly panic attacks
that result from cued and uncued stimuli and the anticipatory anxiety from one attack to the next can greatly affect the normal functioning of an individual.

The two primary treatment modalities for PDA are pharmacologic and nonpharmacologic. Benzodiazepines, the only medication for PDA approved by the Food and Drug Administration, have several advantages: their antipanic properties are evident almost immediately (3); their effectiveness is maintained over "as needed", short, and long-term dosage schedules; they have no long-term adverse effects on any organs; ingested overdoses are virtually non-lethal (14). Gitlin (1990) designates the benzodiazepines as the safest of the psychotropic medications presently in use.

Part of benzodiazepine's efficacy may be a function of its mode of action. Tallman, Thomas, and Gallagher (1978) showed that the benzodiazepines enhance the widespread inhibitory activity of gamma-aminobutyric acid (GABA) in the brain. Moreover, the juxtaposition of the GABA and benzodiazepine receptors on the same receptor complex and their necessary joint stimulation is responsible for the influx of extracellular free chloride ions and the subsequent inhibited firing of those neurons (14). A high concentration of benzodiazepine-GABA receptor complexes is found in the locus ceruleus, the primary noradrenergic nucleus, hyperactivity of which has been considered to be centrally involved in the etiology of PDA (for review, see Gorman et al, 1989). By reducing the norepinephrine activity in the overstimulated projections of the locus ceruleus with
benzodiazepines, an overall attenuation of symptoms, namely a suppression of the spontaneous panic attacks, can be achieved (17).

Alprazolam, a high potency benzodiazepine, has been shown in large trials to be a particularly efficacious treatment modality for PDA (28, 3). Despite the clear benefits of alprazolam, it also has drawbacks. Alprazolam induces true physiological dependence and shows a distinct withdrawal syndrome when discontinued (23). Withdrawal symptoms can include agitation, forgetfulness, tremor, insomnia, nausea, sweating, and tachycardia. There have been only rare instances where benzodiazepine discontinuation has elicited paranoia, severe depression, delerium, or grand mal seizures (14). In addition to the dependence and withdrawal complications, alprazolam therapy has been characterized by high relapse rates (10).

Given its widespread use in the clinical treatment of anxiety disorders, mental health professionals have been proposing several strategies to ameliorate discontinuation symptoms that complicate alprazolam taper. One such method of facilitating withdrawal involves the temporary addiction to other medications such as carbamazepine, imipramine, or buspirone during taper (26). A study by Ries, Roy-Byrne, Ward, Neppe, & Cullison (1989) showed that patients given carbamazepine before rapid discontinuation of benzodiazepines tolerated the taper well with no one reporting significant withdrawal symptoms or side effects. Another suggested treatment strategy consists of modifying taper by changing patients
from an intermediate-acting benzodiazepine (alprazolam) to a longer-acting agent (clonazepam) before the initiation of discontinuation (14,1). While these studies show that medication strategies are helpful when taper is rapid, a slow flexible taper is sufficient to assist discontinuation; however, relapse after discontinuation remains a problem (30, 19).

The major non-pharmacological approach to PDA involves cognitive-behavioral therapy (CBT). A primary target of CBT is to reduce the catastrophic misinterpretations of panic symptoms such as cardiac arrhythmia, breathlessness, and lightheadedness, which may be perceived as heart attack precursors instead of the somatic sensations in normal anxiety responses (9).

Cognitive-behavioral therapy has been shown to have high acute treatment success rates with low relapse rates. For example, Craske, Brown, and Barlow (1991) assessed 41 panic disorder patients with mild or no agoraphobic avoidance who had participated in either progressive muscle relaxation, interoceptive exposure therapy and cognitive restructuring, or a combination of both conditions. Of the patients receiving cognitive restructuring, 81% remained panic-free at two-year follow-up. Similarly, a study examining the treatment of agoraphobia at two years demonstrated that agoraphobics undergoing CBT maintained an improved end-state functioning over 24 months when a spouse was involved with therapy (6).
CBT formulations suggest that the withdrawal symptoms experienced by patients during benzodiazepine taper may be related to the difficulty in discontinuing their medications, in light of PDA patients' heightened anxiety and concern about bodily sensations (e.g., Otto et al., 1992). Several trials integrating CBT methods into alprazolam taper have produced promising results. For example, Otto et al. (1993) assessed the efficacy of a cognitive-behavioral program for 33 patients with PDA who were discontinuing treatment with high potency benzodiazepines. Panic patients randomly assigned to drug condition or drug condition with ten weeks of concurrently taught CBT were tapered off of alprazolam or clonazepam (mean subtherapeutic dose=1.3 mg/day and 1.5 mg/day respectively). Successful discontinuation of benzodiazepine treatment was significantly lower for those receiving slow taper alone (25%) than for those who underwent cognitive-behavioral restructuring during taper (76%); 77% of the latter remained free of benzodiazepines at three-month follow-up. In a similar follow-up study, Bruce et al. (1994) reported that panic disorder patients who received combined alprazolam/CBT experienced fewer symptoms at three months and were overall better responders to alprazolam discontinuation.

Spiegel, Bruce, Gregg, & Nuzzarello (1994) also assessed patients (N=21) who were made panic-free with alprazolam (mean dose=2.2 mg/day) and then assigned to either slow, flexible drug taper or drug taper with 12 weeks of CBT. At the completion of the study, there were no significant differences between the groups
Long-term Effectiveness

Concerning the rate of alprazolam discontinuation; however, at six month follow-up, 50% of the alprazolam-only group (N=10) and none of the combined alprazolam/CBT group (N=10) relapsed and had to reinstate pharmacotherapy. This result suggests that the drug taper protocol was sufficient to increase the discontinuation rate, but the CBT prevented relapse. Another long-term follow-up at one year showed 76% of the patients were medication-free and 85% were panic-free after a CBT model was employed during drug taper (18).

Although these results suggest that CBT can help patients successfully discontinue alprazolam and maintain gains through six month to one-year evaluations, treatments combining psychotherapy and benzodiazepines are not always beneficial. As was shown by Marks et al. (1993) in one large trial, implementing anxiety management techniques and in vivo exposure therapy as treatment supplements did not produce encouraging results. In that study, there were no significant differences in relapse rates between the CBT-only group (56%) and those receiving CBT after drug discontinuation (52%). Consequently, it remains controversial if combined therapy will be as viable a treatment modality as CBT-only over long-term assessments.

To our knowledge, no studies have investigated the effects of combined CBT and alprazolam at long-term follow-up. The purpose of the present study was to evaluate the clinical functioning of combined alprazolam and CBT at two- to four-year assessment and to see if efficacy is maintained. We hypothesized that individuals
Long-term Effectiveness

receiving CBT during taper would be more successful in remaining drug abstinent compared to patients who taper off alprazolam without concurrently taught cognitive-behavioral therapy. We also predicted that members of the combined group would maintain their therapeutic gains through long-term follow-up.

Method

Participants

Participants were recruited from the patient population at the University of Illinois College of Medicine at Peoria who met the DSM-III-R diagnostic criteria for panic disorder with agoraphobia of at least six months' duration. Assessments were made with the Anxiety Disorders Interview Schedule-Revised (ADIS-R) (13) and the Structured Clinical Interview for DSM-III-R-Personality Disorders (SCID-II, Version 1.0) (31). Patients were excluded from the study if they met DSM-III-R criteria for an organic mental syndrome, major mood disorder, or obsessive-compulsive disorder; had been treated previously with cognitive-behavioral therapy for panic disorder; were presently in psychotherapy, or were taking other centrally-acting medications besides alprazolam. Similarly, if patients presented with mental illness, pregnancy, lactation, or a history of psychosis or drug dependency within the past year, they were not included. To be considered for the study, patients had to have alprazolam as their only centrally-acting medication in daily dosages between 1 and 10 mg. They also had to be free of spontaneous panic
attacks for at least four weeks. For those individuals who met all
criteria except these, a washout period followed by alprazolam
stabilization was instituted before their enrollment into the program.

Twenty-four participants were included, four men and 20
women (mean age=38 years, average duration of PDA=12 years). At
screening, of the 15 who were on anxiolytics, 12 were taking
benzodiazepines, and one patient each was taking buspirone,
propranolol, and desipramine.

All participants presented with symptoms at screening despite
being on pharmacotherapy. Patients suffered from a weekly average
of 1.6 panic attacks and 4.6 limited symptom attacks before
alprazolam stabilization. Over 70% of the group complained of
nocturnal panic episodes. Following DSM-III-R criteria, 19% of the
patiens were rated as having mild panic, whereas 52% and 29% of
the patients met the guidelines for moderate and severe panic,
respectively. Agoraphobic avoidance was rated as mild for eight,
moderate for 12, and severe for one of the patients. Forty-eight
percent of the group had one additional anxiety disorder, while nine
percent met criteria for two or three. Specifically, the comorbid
diagnoses included general anxiety disorder (33%), simple phobia
(29%), and social phobia (9%).

Each person was stabilized on alprazolam before enrollment
(mean duration=6.3 weeks, including four weeks following the final
stabilized dosage). The mean alprazolam dose was 2.2 mg/day.
Treatments

After alprazolam stabilization and enrollment, participants were randomly assigned to either an alprazolam and taper with supportive medical management (N=10), or the identical treatment with twelve weeks of concurrently taught cognitive-behavioral therapy (N=14). So as to minimize patients' bias against the drug only condition, all participants were told that the study was comparing two methods of alprazolam administration and discontinuation. Each person consented to random assignment and the institutional review board approved of the handling of human participants.

Treatment integrity was monitored through random assessments of 30% of the cognitive-behavioral and supportive therapy audiotapings. Treatment adherence scales by Barlow and Craske were used to check the cognitive-behavioral sessions. To ensure patient compliance with the pharmacotherapeutic protocol, weekly pill counts, patient diaries of alprazolam use, and serum benzodiazepine levels at two, six, and 15 weeks post-taper were employed.

Pharmacotherapy. Alprazolam maintenance and taper consisted of two phases which were identical for both groups of patients. The stable-dose maintenance phase (mean duration=11.0 weeks) reflected that time during which the patient was maintained on the pre-enrollment dose; the taper phase (mean duration for those who completed taper=6.5 weeks) included a decrease in alprazolam dosages in open label fashion every seven days until either
discontinuation was complete or the patient refused to decrease the dose any further. Depending on the initial maintenance dose, participants’ daily alprazolam intake was tapered down to 2 mg, then to 1.5, 1.0, 0.75, 0.5, 0.375, 0.25, 0.125, and finally 0 mg.

Supportive medical management for patients was provided weekly to both groups by a psychiatrist during the stable-dose and taper phases of alprazolam withdrawal. Follow-up visits consisted of biweekly consultations for three months and then a brief final contact after six months. Extensive precautions were taken to ensure that the psychiatrist was blind to the treatment conditions.

Cognitive-behavioral therapy. Patients in this group differed from their drug-only counterparts solely by the twelve weeks of CBT, which was administered concurrently through a alprazolam taper. Four sessions, participants individually received the CBT in accordance to manuals developed by Barlow and Craske (1989). Treatment included education about panic disorder, diaphragmatic breathing training, cognitive restructuring, and interoceptive exposure. The latter was initiated at the beginning of drug taper whereas the former three aspects of therapy were introduced during the stable-dose phase. With this design, participants did not receive any CBT until the CBT cognitive-behavioral session, after which time, the patient had no contact with the intervening therapists.

Measures

Alprazolam discontinuation. The primary outcome measure was the number of individuals who completed all steps of taper in the
time allotted by the treatment protocol and who did not relapse back on to pharmacotherapy or enroll in alternative PDA treatment throughout the two- to four-year follow-up.

Clinician-rated and self-report assessments were done at baseline, three-month post-taper, and two- to four-year post-taper follow-up. Using the Sheehan Panic and Anticipatory Anxiety Scale, the occurrence of panic attacks or limited symptom attacks during the preceding two weeks, and the intensity of anticipatory anxiety episodes were evaluated (29). Patients' fear of situations was assessed on the Anxiety Disorders Interview Schedule-Fear (13), and their level of agoraphobic avoidance when alone was rated by using the Mobility Inventory for Agoraphobia (8). Cognitive features of PDA were assessed using the Anxiety Sensitivity Index (25), the Agoraphobic Cognitions Questionnaire (7), and the Emotional Control Questionnaire (Rapee, Craske, and Barlow; presented at the 1989 annual meeting of the Association for Advancement of Behavioral Therapy). Depression was measured with the Beck Depression Inventory (4) (see appendices A-G).

Results

Participants

One participant in the combined alprazolam and CBT group did not complete taper due to the discovery that she had been started on a centrally-acting drug regimen other than alprazolam for a medical
condition not related to anxiety. Three patients (two in the drug-only group and one in the combined group) failed to complete all steps of taper. Among the remaining 20 individuals, 16 managed to complete taper with the standard weekly dose reductions, three accomplished taper with one extra week required, and one needed an additional three weeks.

**Measures**

Two types of data analysis were performed: a survival analysis to evaluate discontinuation success between treatment groups and repeated measures analyses of variance (ANOVAs) to assess the efficacy of combined therapy between assessment periods.

**Discontinuation Success.** Figure 1 shows the percentage of patients who achieved and maintained drug and other PDA treatment abstinence through follow-up. Success rates at post-taper were high for both alprazolam-only (80%) and combined therapy groups (92%). At six-month follow-up, while 92% of the combined group continued to remain intervention-free, 60% of their drug-only counterparts had resumed medication. Those who relapsed cited increased panic and limited symptom relief attacks as the reasons for reinstating drug therapy. Assessments at 24-48 months post-taper showed that discontinuation success rates had fallen to 30% and 69.2% for the alprazolam and alprazolam+CBT groups. A survival analysis indicated that discontinuation rates before taper, post-taper, and at 24-48-month follow-up were significantly
different between the two groups (Lee-Desu statistic=10.539, df=1, p<0.005).

**Repeated Measures ANOVAs.** Differences between baseline, 3-month post-taper, and 2- to 4-year follow-up scores on clinician-rated and self-report measures in the combined group were compared using repeated measures ANOVAs. Omnibus tests that were significant, were followed up with planned comparisons using Fisher's two-tailed t-tests. Results from those t-tests are graphically represented in Figures 2-8. Figure 2 shows that scores on the Anxiety Disorders Interview Schedule-Fear differed significantly from baseline to three-month follow-up (t=3.51, df=12, p<0.005), three-month to 24-48-month follow-up (t=9.96, df=11, p<0.001), and from baseline to 24-48-month follow-up (t=12.21, df=12, p<0.001). Mean scores on the Mobility Inventory of Agoraphobia when Alone indicate significance levels from baseline to 3-month (t=4.43, df=12, p<0.005) and baseline to long-term follow-up (t=4.58, df=12, p<0.001)

Similar findings between baseline and 3-month and baseline to 2 to 4 year follow-up were evinced on the other evaluative tests (Figures 4-8). Scores on the Anticipatory Anxiety Scale were significant over the measurement periods (t=2.73, df=12, p<0.05) and (t=2.90, df=11, p<0.05) respectively as did the means from the Beck Depression Inventory (t=2.15, df=12) and (t=2.77, df=11) respectively. The Anxiety Sensitivity Inventory also was effective in detecting changes in patient functioning as was seen by the
significant decrease in scores from baseline to 3 months \( (t=3.46, \text{df}=12, p<0.01) \) and from baseline to 24-48 months \( (t=3.16, \text{df}=11, p<0.01) \). Scores on the Agoraphobic Cognitions Questionnaire reflected a similar decrease \( (t=2.55, \text{df}=12, p<0.05) \) and \( (t=3.80, \text{df}=11, p<0.005) \). Means on the Emotional Control Questionnaire were also significant from baseline to both 3-month \( (t=-2.79, \text{df}=12, p<0.05) \) and 24-48-month follow-up \( (t=-2.87, \text{df}=11, p<0.05) \).

Discussion

This paper presents data from patients with PD who discontinued stable therapeutic doses of alprazolam with and without concurrent CBT. Spiegel et al. (1994) demonstrated that at six month post-taper, those individuals receiving the additional psychotherapy were significantly better than their alprazolam-only counterparts by remaining drug abstinent and panic-free.

The results reported here show that the high successful discontinuation rates seen in the combined group were persistent over two to four years. Nearly 70% of those participants did not need to return to medication and other treatment interventions.

Suggesting that the significant difference between groups at long-term follow-up is necessarily attributable to the CBT, however, is specious, given that no CBT-only group was assessed at the same evaluation points. Studies examining the long-term effectiveness of CBT-only, though, have elucidated clearly the benefits of this
treatment modality with approximately 80% of patients maintaining therapeutic gains (6, 12).

Improvement evident on self-report and clinician-rated measures shows that the success of the alprazolam plus CBT participants to discontinue medication was not due to stoic endurance of symptoms, stubborn refusal to reinstate medication, or greater avoidance of panic-precipitating situations. Significant improvement was seen on most dimensions of PDA, including panic attack number, fear of situations, actual avoidance of situations, anticipatory anxiety, depression, fear of physiological sensations, catastrophic thinking, and locus of control, indicating that end-state functioning was high at two to four-year follow-up. Not only did mean scores remain low as in the anticipatory anxiety scale and the number of panic attacks (zero at baseline, 3-month, and 24-48-month post-taper), but scores showed a general decrease suggesting continued improvement from baseline to post-taper which maintained through follow-up. Scores on the Emotional Control Questionnaire increased over the course of the study which was reflective of patients' conception that emotions were more within their control. Patients were considerably less anxious and depressed, they reported less fear, and their avoidance of situations had decreased significantly. This A+CBT protocol facilitated alprazolam discontinuation and was responsible for clinical changes reflected in high end-state functioning at long-term follow-up.
Several cautions must be employed in interpreting these results, however. For one, although the participant sample was representative of larger N studies of PDA on many features, generalization of the findings should be guarded due to the small sample size. With 23 patients, the power of our statistics is less than optimal. Replication is necessary. Also, our results suggest that combined treatment is effective over the long-term, but without a proper control group, we cannot ascertain what elements of CBT+alprazolam accounted for the change in patient functioning from baseline to follow-up evaluation.

Despite these problems, these data are intriguing and deserve careful consideration. This treatment protocol, which gives PDA patients prompt relief from symptoms and the cognitive-behavioral change to maintain those gains through long-term follow-up, gives mental health professionals an additional treatment option. Combined therapy has been shown to be beneficial at three-month follow-up (5, 21), six-month follow-up (30), and at one-year evaluation (18). Our results provide the long-term (2- to 4-year) data necessary to ensure practitioners that implementing this particular method of integrating CBT and drug taper will produce lasting effects.

Future directions could focus on elucidating the mechanism of action by which integrated therapy has its effects. Other studies could also directly compare efficacies of CBT alone. Combined therapy appears to warrant further research.
References


Appendix A

Structured Interview for Sheehan Panic and Anticipatory Anxiety Scale (Revised for Study)

Subject Name ___________________________ ID ___________________________
Interviewer ___________________________ Date ___________________________

Now I would like to ask you about any panic attacks you may have experienced during the past week. By "panic attack" I mean specifically an episode or spell during which you suddenly felt frightened or extremely uncomfortable and had at least four of the symptoms on the list I will give you in a moment. By "suddenly" I mean that the symptoms reached their maximum intensity within 10 minutes from when you first noticed they were there or were getting worse. It is important that you are clear about how I am defining a panic attack. Are you clear about that? Do you have any questions?

(Rater: Answer any questions before proceeding)

Now please read carefully through the symptoms on this list, noting any you experienced during the past week that came on suddenly along with a feeling of fear or extreme discomfort. Take your time, and let me know when you are finished.

(Rater: Hand patient Symptom List and wait for signal).

A. PANIC ATTACKS:

O.K., now, during the past week, how many episodes in all have you had when you suddenly felt frightened or extremely uncomfortable and experienced at least four of the symptoms on the list? (I will ask you later about episodes when you had fewer than 4 symptoms.)

(Rater: Verify that all of the episodes reported involved at least four symptoms on the list and reached a peak within 10 minutes. Record Number/Week in blank at left.)

TPN _____

1. SITUATIONAL:

Now of those (insert number) attacks, how many occurred when you were in or just about to go into a place or situation that, in your experience, is likely to bring on an attack?

(Number/Week)

SPN _____

SPD _____

associated with those situations) last? (Duration-minutes)
On a scale of 1 to 10, with 1 being the least and 10 being the most anxious or uncomfortable you can imagine, how bad were most of those attacks? (Intensity - Score "0" if subject had no attacks)

2. UNEXPECTED:

So then of the (total number from A) panic attacks you experienced during the past week, (number from A.1) occurred when you were in or about to go into a place or situation that, in your experience, is likely to bring on an attack, and all the others occurred when you were not in or about to go into such a place or situation? Is that correct?

(Rater: If no, clarify and revise answers to A.1 as needed. If yes, proceed).

That would be a total of (calculate number) unexpected panic attacks during the past week; is that right?

(Rater: If no, revise previous answers as needed. If yes, record Number/Week).

How long did most of these unexpected panic attacks last?

(Duration- minutes)

How bad were most of them on the 1 to 10 scale, 1 being the least and 10 being the most uncomfortable you can imagine?

(Intensity - Score "0" if patient had no attacks)

B. LIMITED SYMPTOM ATTACKS:

Now, during the past week did you ever suddenly experience only 1, 2 or 3 of the symptoms on the list, without having a full panic attack? Remember, by "suddenly" I mean that the symptoms reached their maximum intensity within 10 minutes from when you first noticed they were there or were getting worse.

(Rater: If yes, have patient describe worst attack and go over list to make sure there were no more than 3 symptoms. If there were, it may qualify as a panic attack, in which case the answers in Section A may need to be revised.)

In all, during the past week, how many times did you experience episodes or spells of this limited kind? Don't include the full panic attacks we already discussed. (Number/week)
1. SITUATIONAL:

Now of those \( \text{insert number} \) limited attacks, how many occurred when you were in or just about to go into a place or situation that, in your experience, is likely to bring on an attack? 
(Number/Week)

SLN____

How long did most of those episodes (the ones associated with those situations) last? (Duration-minutes)

SLD____

How bad were most of them on the 1 to 10 scale, 1 being the least and 10 being the most uncomfortable you can imagine. 
(Intensity - Score "0" if patient had no attacks)

SLI____

2. UNEXPECTED:

So then of the \( \text{total number from B} \) limited attacks you experienced during the past week, \( \text{number from B.1} \) occurred when you were in or about to go into a place or situation that, in your experience, is likely to bring on an attack, and \text{all the others occurred when you were not in or about to go into such a place or situation? Is that correct?}

(Rater: If no, clarify and revise answers to B.1 as needed. If yes, proceed.)

That would be a total of \( \text{calculate number} \) unexpected limited attacks during the past week; is that right?

(Rater: If no, revise previous answers as needed. If yes, record Number/Week).

ULN____

How long did most of these unexpected limited attacks last? 
(Duration-minutes)

ULD____

How bad were most of them on the 1 to 10 scale, 1 being the least and 10 being the most uncomfortable you can imagine. 
(Intensity - Score "0" if subject had no attacks)

ULI____

C. ANTICIPATORY ANXIETY

Now I would like to get an estimate of how much you have been worrying about having a panic attack. \text{During the past week, approximately what percent of the time when you were awake and were not having a panic attack did you worry about having a panic attack or about going into a situation that, in your experience, is likely to bring on an attack? (% time)}

AAT____
How many separate times during the past week did you have periods of worry about having a panic attack or about going into a situation that might cause a panic attack? (Number/week)

On the average, how anxious or nervous were you during those times? Rate your anxiety or nervousness on a scale of 1 to 10, with 1 being the least and 10 being the most anxious or nervous you can imagine? (Intensity - Score "0" if subject had no attacks)
Appendix B

Because of the copyright restrictions and price, a copy of the Anxiety Disorders Inventory Schedule-Fear could not be obtained.
THE MOBILITY INVENTORY FOR AGORAPHOBIA

Name: ___________________________ Date: ___________________________

Please indicate the degree to which you avoid the following places or situations because of discomfort or anxiety. Rate your amount of avoidance when you are with a trusted companion and when you are alone. Do this by using the following scale.

1. Never avoid
2. Rarely Avoid
3. Avoid about half the time
4. Avoid most of the time
5. Always avoid

(You may use numbers half-way between those listed when you think it is appropriate. For example, 3 1/2 or 4 1/2.)

Write your score in the blanks for each situation or place under both conditions: when accompanied, and, when alone. Leave blank those situations that do not apply to you.

<table>
<thead>
<tr>
<th>PLACES</th>
<th>When accompanied</th>
<th>When alone</th>
</tr>
</thead>
<tbody>
<tr>
<td>Theatres</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Supermarkets</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Classrooms</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treatment centers</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Restaurants</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Museums</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Elevators</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Auditoriums or stadiums</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Parking garages</td>
<td></td>
<td></td>
</tr>
<tr>
<td>High places</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tell how high: _____________</td>
<td></td>
<td></td>
</tr>
<tr>
<td>and tunnel  ________________</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**Long-term Effectiveness**

<table>
<thead>
<tr>
<th>Open spaces:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>(A) Outside (e.g. fields, wide streets, courtyards)</td>
<td></td>
</tr>
<tr>
<td>(B) Inside (e.g. large rooms, lobbies)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Riding In:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>(A) Buses</td>
<td></td>
</tr>
<tr>
<td>(B) Trains</td>
<td></td>
</tr>
<tr>
<td>(C) Subways</td>
<td></td>
</tr>
<tr>
<td>(D) Airplanes</td>
<td></td>
</tr>
<tr>
<td>(E) Boats</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Driving or riding in cars:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>(A) At any time</td>
<td></td>
</tr>
<tr>
<td>(B) On expressways</td>
<td></td>
</tr>
</tbody>
</table>

**SITUATIONS**

<table>
<thead>
<tr>
<th>Standing in lines</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Crossing bridges</td>
<td></td>
</tr>
<tr>
<td>Parties or social gatherings</td>
<td></td>
</tr>
<tr>
<td>Walking on the street</td>
<td></td>
</tr>
<tr>
<td>Staying at home alone</td>
<td>N/A</td>
</tr>
<tr>
<td>Being far away from home</td>
<td></td>
</tr>
<tr>
<td>Other (specify)</td>
<td></td>
</tr>
</tbody>
</table>

We define a panic attack as:

1. a high level of anxiety accompanied by
2. strong body reactions (heart palpitations, sweating, muscle tremors, dizziness, nausea) with
3. the temporary loss of the ability to plan, think, or reason and
4. the intense desire to escape or flee the situation. (Note, this is different from high anxiety or fear alone.)

Please indicate the total number of panic attacks you have had in the last 7 days. ___________________________
Appendix D

ANXIETY SENSITIVITY INDEX

Name: ____________________________

Age: _______ Date: ________________ Sex: M ___ F ___

Listed below are a number of statements describing a set of beliefs. Please read each statement carefully and, on the 0-5 scale given, indicate how much you think each statement is typical of you.

-----0-----------1-----------2-----------3-----------4-----------5-----

Strongly Moderately Slightly Slightly Moderately Strongly
Disagree Disagree Disagree Agree Agree Agree

1. It is important to me not to appear nervous.
2. When I cannot keep my mind on a task, I worry that I might be going crazy.
3. It scares me when I feel 'shaky' (trembling).
4. It scares me when I feel faint.
5. It is important to me to stay in control of my emotions.
6. It scares me when my heart beats rapidly.
7. It embarrasses me when my stomach growls.
8. It scares me when I am nauseous.
9. When I notice that my heart is beating rapidly, I worry that I might have a heart attack.
10. It scares me when I become short of breath.
11. When my stomach is upset, I worry that I might be seriously ill.
12. It scares me when I am unable to keep my mind on a task.
13. Other people notice when I feel shaky.
14. Unusual body sensations scare me.
15. Unusual body sensations scare me.
16. It scares me when I am nervous.
Appendix E

AGORAPHOBIC COGNITIONS QUESTIONNAIRE

Name: ___________________________ Date: ___________________________

Below are some thoughts or ideas that may pass through people’s minds when they are nervous or frightened. Please rate how often each thought occurs to you when you are nervous. Do this by writing the appropriate number from the following scale in the space next to the thought.

1. Thought never occurs.
2. Thought rarely occurs.
3. Thought occurs during half of the times I am nervous.
4. Thought usually occurs.
5. Thought always occurs when I am nervous.

_____ I am going to throw up.
_____ I am going to pass out.
_____ I must have a brain tumor.
_____ I will have a heart attack.
_____ I will choke to death.
_____ I am going to act foolish.
_____ I am going blind.
_____ I will not be able to control myself.
_____ I will hurt someone.
_____ I am going to have a stroke.
_____ I am going to go crazy.
_____ I am going to scream.
_____ I am going to babble or talk funny.
_____ I will be paralyzed by fear.
Appendix F

EMOTIONAL CONTROL QUESTIONNAIRE

Name: ____________________________

Age: ______ Date: ________________ Sex: M __ F __

Listed below are a number of statements describing a set of beliefs. Please read each statement carefully and, on the 0-5 scale given, indicate how much you think each statement is typical of you.

<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Strongly Disagree</td>
<td>Moderately Disagree</td>
<td>Slightly Disagree</td>
<td>Slightly Agree</td>
<td>Moderately Agree</td>
<td>Strongly Agree</td>
</tr>
</tbody>
</table>

1. I can control the degree to which I react to particular situations.
2. How well I cope with difficult situations depends on whether I have outside help.
3. When I am put under stress, I am likely to lose control.
4. I can easily turn a difficult situation into a manageable one.
5. My emotions seem to have a life of their own.
6. I can deal successfully with stressful situations.
7. Whether I can successfully escape a frightening situation is always a matter of chance with me.
8. I can usually influence the degree to which a situation is potentially threatening to me.
9. The degree to which I react to problems is out of my control.
10. The extent to which a difficult situation resolves itself has nothing to do with my actions.
11. There is nothing I can do to stop anxiety once it has started.
12. Any little thing can make me uptight.
13. I feel like I am the victim of my emotions.
14. __________
15. I am able to prevent myself from becoming overly anxious.
This questionnaire consists of 21 groups of statements. After reading each group of statements carefully, circle the number (0, 1, 2 or 3) next to the one statement in each group which best describes the way you have been feeling the past week, including today. If several statements within a group seem to apply equally well, circle each one. Be sure to read all the statements in each group before making your choice.

<p>| | | | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Feel sad.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>I do not feel like a failure.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>I get as much satisfaction out of things as I used to.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>I don't feel particularly guilty.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>I don't feel disappointed in myself.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>I am not being punished.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>I am not as good as I used to be.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>I don't think I am as good as I used to be.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>I don't enjoy things the way I used to.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>I am no more irritating now than I ever was.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>I have not lost interest in other people.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>I am not as interested in other people as I used to be.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>I am not as interested in other people as I am now.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Note:* The rest of the table continues on the back page.
|   | 14 | I don't feel I look any worse than I used to. |
|   | 1  | I am worried that I am looking old or unattractive. |
|   | 2  | I feel that there are permanent changes in my appearance that make me look unattractive. |
|   | 3  | I believe that I look ugly. |
|   | 15 | I can work about as well as before. |
|   | 1  | It takes an extra effort to get started at doing something. |
|   | 2  | I have to push myself very hard to do anything. |
|   | 3  | I can’t do any work at all. |
|   | 16 | I can sleep as well as usual. |
|   | 1  | I don’t sleep as well as I used to. |
|   | 2  | I wake up 1-2 hours earlier than usual and find it hard to get back to sleep. |
|   | 3  | I wake up several hours earlier than I used to and cannot get back to sleep. |
|   | 17 | I don’t get more tired than usual. |
|   | 1  | I get tired more easily than I used to. |
|   | 2  | I get tired from doing almost anything. |
|   | 3  | I am too tired to do anything. |
|   | 18 | My appetite is no worse than usual. |
|   | 1  | My appetite is not as good as it used to be. |
|   | 2  | My appetite is much worse now. |
|   | 3  | I have no appetite at all anymore. |
|   | 19 | I haven’t lost much weight, if any, lately. |
|   | 1  | I have lost more than 5 pounds. |
|   | 2  | I have lost more than 10 pounds. |
|   | 3  | I have lost more than 15 pounds. |
|   |   | I am purposely trying to lose weight by eating less. Yes _____ No _____ |
|   | 20 | I am no more worried about my health than usual. |
|   |   | I am worried about physical problems such as aches and pains; or upset stomach; or constipation. |
|   |   | I am very worried about physical problems and it’s hard to think of much else. |
|   |   | I am so worried about my physical problems that I cannot think about anything else. |
|   | 21 | I have not noticed any recent change in my interest in sex. |
|   |   | I am less interested in sex than I used to be. |
|   |   | I am much less interested in sex now. |
|   |   | I have lost interest in sex completely. |
Figure Legend and Footnote

FIGURE 1. Percentage of Patients Achieving and Maintaining Drug and Other PDA Treatment Abstinence in Alprazolam-Only and Alprazolam Plus Cognitive-Behavioral Therapy Groups at 24 to 48-Month Follow-Up.¹

Footnote:
¹Significant difference between survival distributions from before taper to 24-48 months after taper (Lee-Desu statistic=10.539, df=1, p<0.005).

FIGURES 2-8. Changes in Mean Scores on Self-Report and Clinician-Rated Measures at Baseline, 3-Month Follow-Up, and 24-48-Month Follow-Up in the Combined Treatment Group (Significance Differences Denoted by *).

Long-term Effectiveness  40
Alprazolam + Cognitive-Behavioral Therapy (N=13)
Alprazolam only (N=10)